NSC 42834

CAT: 0804-HY-15480-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-15480-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of Jak2, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.
CAS Number
[195371-52-9]
Product Name Alternative
JAK2 Inhibitor V; Z3
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/NSC-42834.html
Purity
96.85
Solubility
DMSO : ≥ 100 mg/mL|Ethanol : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=CC=C1)C(CCC2=NC=CC=C2)(C)CCC3=NC=CC=C3
Molecular Formula
C23H24N2O
Molecular Weight
344.45
Precautions
H315, H319, H335
References & Citations
[1]Jacqueline Sayyah, Andrew Magis, David A. Ostrov, et al. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth . Mol Cancer Ther 2008;7 (8) :2308-18.|[2]Jacqueline Sayyah, Peter P. Sayeski. Jak2 inhibitors: Rationale and role as therapeutic agents in hematologic malignancies. Current Oncology Reports. 2009, 11 (2) : 117-124.|[3]Ehab Atallah , Srdan Verstovsek . Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Review of Anticancer Therapy. 2009,9 (5) :663-670.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
JAK2

Popular Products